Arvinas Inc ARVN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$6.41 down $0.14, 2.14% at close Nov 6
Last close · Previous close $6.55
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.10Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$6.41down $0.14, 2.14%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$6.55Nov 5
- Volume1.21MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume879.15KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $6.38 to $14.51; now $6.41
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ARVN trailed the S&P 500 in all 6 periods.
| Period | ARVN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ARVN: down 12.3% S&P 500: down 5.6% | ARVN trailed the S&P 500 by 6.7 percentage points Trailed |
| 3M | ARVN: down 26.2% S&P 500: down 4.1% | ARVN trailed the S&P 500 by 22.1 percentage points Trailed |
| YTD | ARVN: down 46.0% S&P 500: up 8.7% | ARVN trailed the S&P 500 by 54.7 percentage points Trailed |
| 1Y | ARVN: down 35.9% S&P 500: up 10.9% | ARVN trailed the S&P 500 by 46.8 percentage points Trailed |
| Long term | ||
| 3Y | ARVN: down 62.1% S&P 500: up 75.0% −27.7% vs +20.5% a year | ARVN trailed the S&P 500 by 137.1 percentage points Trailed |
| 5Y | ARVN: down 93.0% S&P 500: up 67.8% −41.3% vs +10.9% a year | ARVN trailed the S&P 500 by 160.8 percentage points Trailed |
$10,000 invested in ARVN 5 years ago (Nov 5, 2021) would be worth about $699 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
ARVN trailed the S&P 500 in all 6 periods.
| Period | ARVN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ARVN: down 12.3% S&P 500: down 5.6% | ARVN trailed the S&P 500 by 6.7 percentage points Trailed |
| 3M | ARVN: down 26.2% S&P 500: down 4.3% | ARVN trailed the S&P 500 by 21.9 percentage points Trailed |
| YTD | ARVN: down 46.0% S&P 500: up 7.8% | ARVN trailed the S&P 500 by 53.8 percentage points Trailed |
| 1Y | ARVN: down 35.9% S&P 500: up 9.7% | ARVN trailed the S&P 500 by 45.6 percentage points Trailed |
| Long term | ||
| 3Y | ARVN: down 62.1% S&P 500: up 68.8% −27.7% vs +19.1% a year | ARVN trailed the S&P 500 by 130.9 percentage points Trailed |
| 5Y | ARVN: down 93.0% S&P 500: up 56.9% −41.3% vs +9.4% a year | ARVN trailed the S&P 500 by 149.9 percentage points Trailed |
$10,000 invested in ARVN 5 years ago (Nov 5, 2021) would be worth about $699 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$107.87
Closing high on . Now 94.1% below that record.
Split-adjusted daily closes since Sep 27, 2018.
Stock splits
ARVN hasn’t split since its price history begins in 2018.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $275.30Mdown 11.8%
- Net income
- −$9.50M
- Diluted EPS
- −$0.10
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $59.20M | −$45.10M | −$0.63 |
| Q1 FY25 (Mar 31, 2025) | $188.80M | $82.90M | $1.14 |
| Q2 FY25 (Jun 30, 2025) | $22.40M | −$61.20M | −$0.84 |
| Q3 FY25 (Sep 30, 2025) | $41.90M | −$35.10M | −$0.48 |
| Q4 FY25 (Dec 31, 2025) | $9.50M | −$67.40M | −$0.96 |
| Q1 FY26 (Mar 31, 2026) | $15.60M | −$57.60M | −$0.90 |
| Q2 FY26 (Jun 30, 2026) | $249.70M | $169.40M | $2.58 |
| Q3 FY26 (Sep 30, 2026) | $500.00K | −$53.90M | −$0.82 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $53.60M | −$191.00M | −$3.82 |
| FY22 (Dec 31, 2022) | $131.40M | −$282.50M | −$5.31 |
| FY23 (Dec 31, 2023) | $78.50M | −$367.30M | −$6.62 |
| FY24 (Dec 31, 2024) | $263.40M | −$198.90M | −$2.77 |
| FY25 (Dec 31, 2025) | $262.60M | −$80.80M | −$1.14 |
Margins
- Gross 96.7%
- Operating −12.1%
- Net −3.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$159.80MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$158.30MLast 12 months
- Capital spending$1.50MLast 12 months
- −58.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $73.00MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$73.00MLast 12 months
Balance sheet
- $558.40MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$7.40MAs of Sep 30, 2026
- Net cash$551.00MAs of Sep 30, 2026
- 8.39As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −2.0%Last 12 months
Over the last 12 months, Arvinas lost money: its net loss was 2.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −1.4%Last 12 months
Over the last 12 months, Arvinas’s net loss was 1.4% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Arvinas Inc
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC ® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Connecticut, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ARVN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ARVN stock FAQ
What is ARVN stock’s price today?
Arvinas (ARVN) traded at $6.41 at the close on , down $0.14 (2.14%) from the previous close of $6.55. Over the past 52 weeks it has traded between $6.38 and $14.51.
If you invested $1,000 in ARVN 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ARVN on would be worth about $70 at the close on , a total return of −93.0%. The same $1,000 would be worth $641 if invested one year ago. Past performance doesn’t predict future returns.
What is ARVN’s P/E ratio?
ARVN’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.10).
How much revenue does Arvinas make?
Arvinas reported $275.3 million of revenue over the four quarters to , down 11.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $500.0 thousand, down 98.8% from a year earlier.
Is Arvinas profitable?
Not over the four quarters to . Arvinas reported a net loss of $9.5 million across those four quarters on $275.3 million of revenue.
What are ARVN’s earnings per share?
ARVN’s diluted earnings per share were −$0.10 over the four quarters to , compared with −$0.81 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.82 per share, against −$0.48 a year earlier (how EPS works).
Does ARVN pay a dividend?
Arvinas hasn’t paid a dividend in the last twelve months.
What is ARVN’s 52-week high and low?
Over the past 52 weeks ARVN has traded as low as $6.38 and as high as $14.51. At $6.41 at the close on , it is 55.8% below that high and 0.5% above the low.
What is ARVN’s all-time high?
ARVN’s highest closing price was $107.87 on , adjusted for stock splits. At $6.41 at the close on , it is 94.1% below that record.
Has ARVN stock ever split?
No. ARVN hasn’t split since its price history begins in 2018.
How has ARVN stock performed?
Including dividends and measured to the close on , ARVN has returned −46.0% so far this year and −35.9% over the past year, and −93.0% over five years (−41.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Arvinas in?
Arvinas is in the Healthcare sector and the Biotechnology industry, and is headquartered in Connecticut, USA.
What exchange does ARVN trade on?
Arvinas trades on the Nasdaq under the ticker symbol ARVN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.